CD14 and myeloid sarcoma: In light of these conflicting findings, a few shortages of the previous studies have to be stressed, such as analysis of a mixed MS cohort without distinction between progression forms (26) or disease activity (24) and analysis of pre-purified, monocyte-enriched blood fractions, like peripheral blood mononuclear cells (PBMCs) (23, 27, 28) or CD14+ leukocyte fraction (26).